TISLELIZUMAB

Search structure
Synonyms:
Status: Phase 3
Entry Type: Antibody
Molecule Category: UNKNOWN
UNII: 0KVO411B3N

Pharmacology

Action Mechanism of Action Reference
INHIBITOR Programmed cell death protein 1 inhibitor Other Other PubMed
Primary Target
programmed cell death 1 (CD279)

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Neoplasms 3 D009369 ClinicalTrials
Carcinoma, Non-Small-Cell Lung 3 D002289 ClinicalTrials
Esophageal Neoplasms 3 D004938 ClinicalTrials
Small Cell Lung Carcinoma 3 D055752 ClinicalTrials
Urinary Bladder Neoplasms 3 D001749 ClinicalTrials
Urinary Bladder Neoplasms 3 D001749 ClinicalTrials
Esophageal Neoplasms 3 D004938 ClinicalTrials
Neoplasms 3 D009369 ClinicalTrials
Hodgkin Disease 3 D006689 ClinicalTrials
Urinary Bladder Neoplasms 3 D001749 ClinicalTrials
Hodgkin Disease 3 D006689 ClinicalTrials
Lymphoma, Large B-Cell, Diffuse 3 D016403 ClinicalTrials
Carcinoma, Hepatocellular 3 D006528 ClinicalTrials
Nasopharyngeal Neoplasms 2 D009303 ClinicalTrials
Cholangiocarcinoma 2 D018281 ClinicalTrials
Lymphoma 2 D008223 ClinicalTrials
Lung Neoplasms 2 D008175 ClinicalTrials
Triple Negative Breast Neoplasms 2 D064726 ClinicalTrials
Lymphoma, Non-Hodgkin 2 D008228 ClinicalTrials
Head and Neck Neoplasms 2 D006258 ClinicalTrials
Stomach Neoplasms 2 D013274 ClinicalTrials
Uterine Cervical Neoplasms 2 D002583 ClinicalTrials
Biliary Tract Neoplasms 2 D001661 ClinicalTrials
Breast Neoplasms 2 D001943 ClinicalTrials
Ovarian Neoplasms 2 D010051 ClinicalTrials
Melanoma 2 D008545 ClinicalTrials
Pancreatic Neoplasms 2 D010190 ClinicalTrials
Leukemia 1 D007938 ClinicalTrials

Cross References

Resources Reference
CAS NUMBER 1858168-59-8
ChEMBL CHEMBL4297840
FDA SRS 0KVO411B3N
Guide to Pharmacology 9592
CONTENTS